Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT06191744
Title	Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCORE™FL-2)
Acronym	EPCORE™FL-2
Recruitment	Recruiting
Gender	both
Phase	Phase III
Variant Requirements	No
Sponsors	AbbVie
Indications	follicular lymphoma
Therapies	Epcoritamab-bysp + Lenalidomide + Rituximab Bendamustine + Obinutuzumab Lenalidomide + Rituximab Cyclophosphamide + Doxorubicin + Obinutuzumab + Prednisone + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Bendamustine + Rituximab
Age Groups:	adult \| senior
Covered Countries	USA \| TUR \| SWE \| SVK \| ROU \| POL \| NZL \| NLD \| ITA \| ISR \| HUN \| HRV \| GRC \| GBR \| FRA \| ESP \| DNK \| DEU \| CZE \| BGR \| BEL \| AUS